Tufts CSDD Releases Findings from Diabetes Study
BOSTON, MA - Whereas scores of new diabetes and non-diabetes endocrine drugs have been launched since the mid-1990s, and the demand for new therapies continues to grow, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development, according to results of a new study conducted by the
- Mean clinical development time for diabetes drugs increased by 1.3 years from 2002-08 to 2009-15.
- Of the new diabetes drugs approved from 1995-15, 15% received a priority review designation from the FDA, compared to 50% for non-diabetes endocrine drugs and 46% for all non-endocrine drugs.
- The likelihood that a diabetes drug entering clinical testing would transition to Phase III testing was 12.8%, vs. 21.1% for all drugs.
- The likelihood of approval for a diabetes drug entering Phase III was 60%, compared to 56% for all drugs.
To purchase a single report or subscription, please visit our
website
.
About The Tufts Center for the Study of Drug Development
The
Tufts Center for the Study of Drug Development
at Tufts University provides strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of pharmaceutical development, review, and utilization. Tufts CSDD, based in Boston, conducts a wide range of in-depth analyses on pharmaceutical issues and hosts symposia, workshops, and public forums, and publishes Tufts CSDD Impact Reports, a bi-monthly newsletter providing analysis and insight into critical drug development issues.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025